Patents by Inventor Gerard M. Sullivan

Gerard M. Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200002432
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20190315737
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: November 28, 2018
    Publication date: October 17, 2019
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20190144465
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: May 16, 2019
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • Publication number: 20190142941
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 16, 2019
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Publication number: 20190119247
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 25, 2019
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20190055264
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: February 21, 2019
    Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
  • Publication number: 20180251426
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 6, 2018
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, William J. McClellan
  • Publication number: 20180221363
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20180140595
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: November 3, 2017
    Publication date: May 24, 2018
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9877958
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: January 30, 2018
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9844547
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: December 19, 2017
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20170296531
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 7, 2015
    Publication date: October 19, 2017
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers
  • Publication number: 20170182179
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 29, 2017
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch
  • Publication number: 20170158666
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: July 25, 2016
    Publication date: June 8, 2017
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20170096424
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: June 30, 2016
    Publication date: April 6, 2017
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • Publication number: 20160339117
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 24, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Patent number: 9493431
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: November 15, 2016
    Assignee: ABBVIE INC.
    Inventors: Aaron R. Kunzer, Steven W. Elmore, Gerard M. Sullivan
  • Publication number: 20160304451
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: February 19, 2016
    Publication date: October 20, 2016
    Inventors: Steven W. Elmore, Aaron R. Kunzer, Robert A. Mantei, Andrew J. Souers, Gerard M. Sullivan, Gary T. Wang, Le Wang, Michael D. Wendt
  • Patent number: 9403822
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 2, 2016
    Assignee: ABBVIE INC.
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J Souers, Nathaniel D. Catron, Gerard M. Sullivan